Targeting Acute Myeloid Leukemia
Enasidenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months. The U.S....
Progress Against Cancer
Enasidenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months. The U.S....
The FDA decision means the immune checkpoint inhibitor nivolumab is now approved for seven types of cancer. Use of...
The U.S. Food and Drug Administration has approved the first of a new type of immunotherapy called CAR T-cell...
The FDA has approved a new HER2-targeted therapeutic for the treatment of certain patients with early-stage breast cancer. The...
The FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer. The...
The FDA’s new approval for the immunotherapeutic pembrolizumab is the first based entirely on a tumor biomarker rather than...
Avelumab is the fourth immune checkpoint inhibitor to get FDA approval to treat certain patients with bladder cancer. In...
The FDA has approved a new immune checkpoint inhibitor, durvalumab, for the treatment of certain bladder cancer patients. The...
The approval expands the use of the anticancer therapeutic regorafenib (Stivarga) to a third cancer type. It is the...
The U.S. Food and Drug Administration approval of niraparib means there are now three PARP inhibitors that can be...